The first month of 2025 is behind us and ReBlood Rx is excited for what the rest of the year has in store! Our team has come into the new year with a full heaHappy Holidays from ReBlood Rx! We hope your 2025 has been productive and memorable. For our last update of the year, we saved the biggest news for last. December brought a milestone we’ve been working toward behind the scenes, and we’re proud to finally share it!d of steam and are looking to continue the momentum from 2024. We are getting closer and closer to bringing our innovation to the world and want to thank all of our mentors, advisors, partners and team for your continued support and guidance, we couldn’t do this without you!
NATO DIANA 2026 Challenge Program Cohort!
This month, NATO DIANA announced the companies selected for the 2026 Challenge Programme Cohort, and ReBlood Rx is honored to be included.
NATO DIANA, works to identify and accelerate dual-use technologies that address critical defense and security challenges across the Alliance. Over the next several months, DIANA’s Accelerator Program will bring innovators together at accelerator sites across Europe and North America, providing technical guidance, operational feedback, and access to a broad network of mentors and users.
Being selected affirms the importance of our mission: making oxygen delivery possible in environments where blood is limited. Our hemoglobin-based oxygen carrier represents a potential solution for both civilian and defense settings, and DIANA provides an opportunity to refine and evaluate that solution in mission-relevant contexts.
Why DIANA Matters for ReBlood Rx!
Participating in the Challenge Programme gives us access to:
- Guidance from DIANA’s network of experts, mentors, and test centres
- Insights from defence end-users to shape our technology for operational needs
- A clearer pathway toward dual-use adoption
- Funding to advance our work during the Accelerator Programme
- Potential opportunities for additional testing and evaluation support
- A transatlantic network of innovators and partners
DIANA’s goal is to help innovators deepen technological readiness, navigate complex defense procurement pathways, and build solutions that can scale across both commercial and defense markets. This aligns directly with our focus on developing a shelf-stable oxygen-carrying product that performs reliably where blood is not an option.
Acknowledging Our Regulatory Partners
As we prepare to enter the DIANA Accelerator, regulatory readiness becomes even more important. We want to extend a sincere thank you to Kristy Longpre and Mark Hughes for their continued support and regulatory expertise. Their guidance has been instrumental in helping us refine our approach with the FDA’s Center for Veterinary Medicine and move closer to a validated protocol for our upcoming safety studies.
Their work not only advances our core development goals, but also positions us to make the most of the opportunities DIANA provides. We’re grateful for their partnership and look forward to building on this foundation as DIANA accelerates our progress in 2026.
Priorities for 2026
As we enter the Accelerator Program, our priorities include:
- Finalizing our large-animal safety study protocol
- Strengthening our manufacturing processes to support scale
- Preparing technical evidence that aligns with DIANA’s testing expectations
- Engaging with operational experts to map use cases across NATO medical and logistics environments
- Continuing our work with our various partners
Thank you all for your continued support!